Arsanis Provides Update Following Completion of Planned Interim Analysis of Phase 2 Clinical Trial of ASN100
Trial Unlikely to Meet Primary Efficacy Endpoint; Arsanis to Cease Trial Enrollment and Evaluate Complete Clinical Trial Dataset Arsanis to Continue Focus on Development of ASN500 for Prevention of RSV Infection WALTHAM, Mass. and VIENNA, Austria, June 28 …